{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:30:42Z","timestamp":1770697842621,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clgc.2016.12.016","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T18:18:39Z","timestamp":1482430719000},"page":"384-390.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Angiotensin Inhibitors as Treatment of Sunitinib\/Pazopanib-induced Hypertension in\u00a0Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"15","author":[{"given":"Patrick","family":"Penttil\u00e4","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhana","family":"Rautiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuija","family":"Poussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katriina","family":"Peltola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petri","family":"Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.12.016_bib1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","article-title":"Hypertension as a predictive factor of sunitinib activity","volume":"18","author":"Rixe","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.12.016_bib2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.12.016_bib3","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","article-title":"Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors","volume":"17","author":"Rini","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.12.016_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jch.12273","article-title":"Incidence and risk of sorafenib-induced hypertension: a\u00a0systematic review and meta-analysis","volume":"16","author":"Li","year":"2014","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clgc.2016.12.016_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/0284186X.2010.543696","article-title":"Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma","volume":"50","author":"Bono","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2016.12.016_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00005344-200411000-00016","article-title":"Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants","volume":"44","author":"Wei","year":"2004","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.clgc.2016.12.016_bib7","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00005344-199606000-00011","article-title":"Effects of vascular endothelial growth factor on hemodynamics and cardiac performance","volume":"27","author":"Yang","year":"1996","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.clgc.2016.12.016_bib8","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","article-title":"Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor","volume":"14","author":"Steeghs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.12.016_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm1108-1187","article-title":"Angiogenesis factors and preeclampsia","volume":"14","author":"Dechend","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2016.12.016_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2016.12.016_bib11","doi-asserted-by":"crossref","first-page":"e57475","DOI":"10.1371\/journal.pone.0057475","article-title":"Metabolic factors associated with risk of renal cell carcinoma","volume":"8","author":"Haggstrom","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2016.12.016_bib12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.12.016_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI16645","article-title":"Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth","volume":"112","author":"Egami","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clgc.2016.12.016_bib14","first-page":"355","article-title":"Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities","volume":"22","author":"Noguchi","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clgc.2016.12.016_bib15","first-page":"6038","article-title":"Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis","volume":"9","author":"Noguchi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.12.016_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/1568009043332790","article-title":"Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy","volume":"4","author":"Yoshiji","year":"2004","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clgc.2016.12.016_bib17","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/sj.bjc.6605866","article-title":"Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?","volume":"103","author":"Dolley-Hitze","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.12.016_bib18","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.12.016_bib19","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.12.016_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.12.016_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.clgc.2016.12.016_bib22","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.12.016_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","article-title":"Angiotensin receptors: a new role in cancer?","volume":"16","author":"Deshayes","year":"2005","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.clgc.2016.12.016_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/jhh.2009.21","article-title":"Angiotensin inhibition and malignancies: a review","volume":"23","author":"Rosenthal","year":"2009","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.clgc.2016.12.016_bib25","first-page":"4176","article-title":"Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis","volume":"62","author":"Miyajima","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2016.12.016_bib26","doi-asserted-by":"crossref","first-page":"901371","DOI":"10.1155\/2014\/901371","article-title":"Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma","volume":"2014","author":"Verhoest","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clgc.2016.12.016_bib27","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jamcollsurg.2007.01.067","article-title":"Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma","volume":"204","author":"Arafat","year":"2007","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.clgc.2016.12.016_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/156800911795538084","article-title":"Impact of renin-angiotensin system in hepatocellular carcinoma","volume":"11","author":"Yoshiji","year":"2011","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316303627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:25Z","timestamp":1761564445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316303627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1558767316303627"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.12.016","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin Inhibitors as Treatment of Sunitinib\/Pazopanib-induced Hypertension in\u00a0Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}